These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25605266)

  • 1. Modification of Antitumor Immunity and Tumor Microenvironment by Resveratrol in Mouse Renal Tumor Model.
    Chen L; Yang S; Liao W; Xiong Y
    Cell Biochem Biophys; 2015 Jun; 72(2):617-25. PubMed ID: 25605266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resveratrol induces the suppression of tumor-derived CD4+CD25+ regulatory T cells.
    Yang Y; Paik JH; Cho D; Cho JA; Kim CW
    Int Immunopharmacol; 2008 Apr; 8(4):542-7. PubMed ID: 18328445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
    Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
    J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
    Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
    Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD8+ T cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL/Fas signaling pathway and, combined with GM‑CSF and IL‑12, enhance the anti‑renal cortical adenocarcinoma effect.
    Xu HY; Li N; Yao N; Xu XF; Wang HX; Liu XY; Zhang Y
    Oncol Rep; 2019 Aug; 42(2):866-879. PubMed ID: 31233203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.
    Wigginton JM; Gruys E; Geiselhart L; Subleski J; Komschlies KL; Park JW; Wiltrout TA; Nagashima K; Back TC; Wiltrout RH
    J Clin Invest; 2001 Jul; 108(1):51-62. PubMed ID: 11435457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.
    Gigante M; Mandic M; Wesa AK; Cavalcanti E; Dambrosio M; Mancini V; Battaglia M; Gesualdo L; Storkus WJ; Ranieri E
    J Immunother; 2008 Apr; 31(3):254-62. PubMed ID: 18317362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-7 inhibits tumor growth by promoting T cell-mediated antitumor immunity in Meth A model.
    Tang JC; Shen GB; Wang SM; Wan YS; Wei YQ
    Immunol Lett; 2014; 158(1-2):159-66. PubMed ID: 24406503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing whole-tumor cell vaccination by engaging innate immune system through NY-ESO-1/dendritic cell interactions.
    Xu L; Zheng J; Nguyen DH; Luong QT; Zeng G
    J Immunother; 2013 Oct; 36(8):412-22. PubMed ID: 23994888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
    Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
    Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
    Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
    Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.
    Shibahara I; Saito R; Zhang R; Chonan M; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Kanehira M; Kikuchi T; So T; Watanabe T; Takahashi H; Iwabuchi E; Tanaka Y; Shibahara Y; Sasano H; Ishii N; Tominaga T
    Mol Cancer; 2015 Feb; 14():41. PubMed ID: 25744203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape.
    Rayman P; Uzzo RG; Kolenko V; Bloom T; Cathcart MK; Molto L; Novick AC; Bukowski RM; Hamilton T; Finke JH
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S81-7. PubMed ID: 10685665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models.
    Zhou Y; Fu C; Kong Y; Pan D; Wang Y; Huang S; Li Z; Ning Z; Lu X; Shan S; Xin L
    Anticancer Drugs; 2019 Oct; 30(9):909-916. PubMed ID: 30998512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory activity of resveratrol: discrepant in vitro and in vivo immunological effects.
    Gao X; Deeb D; Media J; Divine G; Jiang H; Chapman RA; Gautam SC
    Biochem Pharmacol; 2003 Dec; 66(12):2427-35. PubMed ID: 14637200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
    Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
    Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.
    Sayers TJ; Brooks AD; Lee JK; Fenton RG; Komschlies KL; Wigginton JM; Winkler-Pickett R; Wiltrout RH
    J Immunol; 1998 Oct; 161(8):3957-65. PubMed ID: 9780164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.